On the Record · Boston Scientific
Boston Scientific acquisitions, on the record
The businesses Boston Scientific bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Apollo Endosurgery, Inc.Word for word“In the second quarter of 2023, we completed the acquisition of Apollo Endosurgery, Inc., a public company that has developed and commercialized endoscopic suturing devices including OverStitch™ Endoscopic Suturing Systems and X-Tack™ Endoscopic HeliX Tacking Systems and endobariatric devices including the Apollo ESG™ and Apollo REVISE™ Systems, the first devices authorized by the FDA for endoscopic sleeve gastroplasty and endoscopic bariatric revision procedures, as well as the Orbera™ ® Intragastric Balloon for endoscopic weight management.” 10-K for 2023 | acquisition | In the second quarter of 2023 | — |
Relievant Medsystems, Inc.Word for word“In addition, in the fourth quarter of 2023, we completed the acquisition of Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept™ Intraosseous Nerve Ablation System, the only FDA-cleared system to treat vertebrogenic pain, a form of chronic low back pain.” 10-K for 2023 | acquisition | In the fourth quarter of 2023 | — |
Acotec Scientific Holdings Limited (majority stake)Word for word“In the first quarter of 2023, we acquired a majority stake investment in Acotec Scientific Holdings Limited (Acotec), a publicly traded Chinese manufacturer of drug-coated balloons and other products used in the treatment of vascular and other diseases, complementing our existing Peripheral Interventions portfolio.” 10-K for 2023 | acquisition | In the first quarter of 2023 | — |
Axonics, Inc.Word for word“On January 8, 2024, we announced our entry into a definitive agreement to acquire Axonics, Inc. (Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction.” 10-K for 2023 | agreed acquisition | — | — |
pathology businessWord for word“as well as the divestiture of our pathology business during the second quarter of 2023 and our acquisition of Baylis Medical Company Inc. (Baylis Medical) during the first quarter of 2022, for which there is less than a full period of comparable net sales.” 10-K for 2023 | divestiture | during the second quarter of 2023 | — |
Axonics, Inc. (Axonics)Word for word“In the fourth quarter of 2024, we completed the acquisition of Axonics, Inc. (Axonics), a publicly traded medical technology company primarily focused on the development and commercialization of devices to treat urinary and bowel dysfunction.” 10-K for 2024 | acquisition | In the fourth quarter of 2024 | — |
Silk Road Medical, Inc. (Silk Road Medical)Word for word“In the third quarter of 2024, we completed our acquisition of Silk Road Medical, Inc. (Silk Road Medical), a publicly traded medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally-invasive procedure called transcarotid artery revascularization.” 10-K for 2024 | acquisition | In the third quarter of 2024 | — |
endoluminal vacuum therapy portfolio of B. Braun Medical Inc.Word for word“Operational net sales growth included organic net sales growth of 8.0 percent in 2024, and the positive impact of 100 basis points from our acquisition of Apollo and the divestiture of our pathology business in the second quarter of 2023, and our acquisition of the endoluminal vacuum therapy portfolio of Braun in the first quarter of 2024.” 10-K for 2024 | acquisition | first quarter of 2024 | — |
Acotec Scientific Holdings Limited (Acotec)Word for word“In 2023, relevant acquisitions and divestitures included our majority stake investment in Acotec Scientific Holdings Limited (Acotec) and the acquisitions of Apollo Endosurgery, Inc. (Apollo) and Relievant Medsystems, Inc. (Relievant) during the first, second and fourth quarters of 2023, respectively, as well as the divestiture of our pathology business during the second quarter of 2023.” 10-K for 2024 | acquisition | — | — |
Apollo Endosurgery, Inc. (Apollo)Word for word“In 2023, relevant acquisitions and divestitures included our majority stake investment in Acotec Scientific Holdings Limited (Acotec) and the acquisitions of Apollo Endosurgery, Inc. (Apollo) and Relievant Medsystems, Inc. (Relievant) during the first, second and fourth quarters of 2023, respectively, as well as the divestiture of our pathology business during the second quarter of 2023.” 10-K for 2024 | acquisition | — | — |
Relievant Medsystems, Inc. (Relievant)Word for word“Operational net sales growth included organic net sales growth of 2.7 percent in 2024, and the positive impact of 1,100 basis points from our acquisition of Relievant in the fourth quarter of 2023.” 10-K for 2024 | acquisition | fourth quarter of 2023 | — |
Cryterion Medical, Inc. (Cryterion)Word for word“The impairment charges recorded in 2024 were primarily associated with amortizable intangible assets established in connection with our acquisitions of Cryterion Medical, Inc. (Cryterion) and Devoro Medical, Inc. (Devoro), which were integrated into our Electrophysiology and Peripheral Interventions business units, respectively.” 10-K for 2024 | acquisition | — | — |
Devoro Medical, Inc. (Devoro)Word for word“The impairment charges recorded in 2024 were primarily associated with amortizable intangible assets established in connection with our acquisitions of Cryterion Medical, Inc. (Cryterion) and Devoro Medical, Inc. (Devoro), which were integrated into our Electrophysiology and Peripheral Interventions business units, respectively.” 10-K for 2024 | acquisition | — | — |
Bolt Medical, Inc.Word for word“In the second quarter of 2025, we completed our acquisition of the remaining shares of Bolt Medical, Inc. (Bolt Medical), the developer of an intravascular lithotripsy advanced laser-based platform for the treatment of coronary and peripheral artery disease.” 10-K for 2025 | acquisition | In the second quarter of 2025 | — |
SoniVie Ltd.Word for word“In addition, we completed the acquisition of the remaining shares of SoniVie Ltd. (SoniVie), a privately held medical device company that has developed the TIVUS™ Intravascular Ultrasound System.” 10-K for 2025 | acquisition | — | — |
Penumbra, Inc.Word for word“The definitive agreement, entered into on January 15, 2026, to acquire Penumbra, for approximately $14.500 billion, which is expected to close during 2026, subject to customary closing conditions.” 10-K for 2025 | agreed acquisition | January 15, 2026 | approximately $14.500 billion |
Nalu Medical, Inc.Word for word“On January 27, 2026, we completed our acquisition of 100 percent of Nalu Medical, Inc. (Nalu Medical), a privately held medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic pain.” 10-K for 2025 | acquisition | January 27, 2026 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2016-12-31 | $408 million | — | $208 million |
| 2017-12-31 | $560 million | — | $308 million |
| 2018-12-31 | $1.45 billion | $0 | $942 million |
| 2019-12-31 | $4.38 billion | $90 million | $2.22 billion |
| 2020-12-31 | $3 million | $15 million | — |
| 2021-12-31 | $2.26 billion | $826 million | $2.06 billion |
| 2022-12-31 | $1.54 billion | $5 million | $1.03 billion |
| 2023-12-31 | $1.81 billion | $0 | $1.45 billion |
| 2024-12-31 | $4.64 billion | $0 | $2.79 billion |
| 2025-12-31 | $1.59 billion | — | $1.06 billion |
Deal filings since 2016
- 2026-02-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-01-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-02-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-02-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-01-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-03-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-05-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-04-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-02-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-12-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-11-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-02-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-12-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-11-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-08-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-02-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-08-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-02-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Boston Scientific’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-17. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.